| TA与MA方案治疗初治急性髓性白血病疗效比较 |
| |
| 引用本文： | 古茂群,张雄,刘传勇. TA与MA方案治疗初治急性髓性白血病疗效比较[J]. 河北医学, 2007, 13(1): 13-15 |
| |
| 作者姓名： | 古茂群 张雄 刘传勇 |
| |
| 作者单位： | 广东省茂名市人民医院血液科,广东,茂名,525000;广东省茂名市人民医院血液科,广东,茂名,525000;广东省茂名市人民医院血液科,广东,茂名,525000 |
| |
| 摘 要： | 目的:比较吡柔比星(pirarubicin,THP)联合阿糖胞苷(cytarabine,Ara-c)(TA组)和米托蒽醌(mitoxantrone,MIT)联合阿糖胞苷(MA组)治疗初治急性髓性白血病的疗效与不良反应.方法:对2002年6月至2005年6月住院的初治急性髓性白血病患者(M3除外),采用以TA或MA的联合化疗方案进行治疗,共86例.其中TA35例,MA51例.结果:TA组与MA组的完全缓解率分别为84.6%,82.4%,一个疗程完全缓解率分别为75.2%,72.7%,总有效率分别为88.6%,86.2%,差异均无统计学意义(P＞0.05).结论:对初治的急性髓性白血病,THP为主的联合化疗方案和MIT为主的联合化疗方案均可取得满意的疗效,TA方案较MA方案更为安全.
|
| 关 键 词： | 白血病 粒细胞 药物疗法 阿霉素 米托蒽醌 |
| 文章编号： | 1006-6233(2007)01-0013-03 |
Comparative Analysis on the Curative Effect Between TA or MA Regimen in de novo Acute Myelogenic Leukemia |
| |
| GU Mao-qun,ZHANG Xiong,LIU Chuan-yong. Comparative Analysis on the Curative Effect Between TA or MA Regimen in de novo Acute Myelogenic Leukemia[J]. Hebei Medicine, 2007, 13(1): 13-15 |
| |
| Authors: | GU Mao-qun ZHANG Xiong LIU Chuan-yong |
| |
| Abstract: | Objective:To compare the efficacy and adverse effects of pirarubicin plus cytarabine(TA)with mitoxantrone plus cytarabine(MA) in the treatment of acute myelogenic leukemia(AML).Method: 86 in patients diagnosed as acute myeloid leukemia between January 2002 to December 2005 were treated with pirarubicin plus cytarabine(TA) mitoxantrone plus cytarabine(MA) while 35 were TA or resistant to MA.Result: The complete remission(CR) rate was 84.6% and 82.4% in TA and MA treated group,respectively.The CR rate in the first course of chemotherapy was 75.2% and 72.7%,and the total response rate was 88.6 % and 86.2 % in TA and MA group.There was no significant difference between the two groups(P>0.05).Conclusion: Satisfactory curative effect can be obtained with both TA and MA regimens in denovo acute myelogenic leukemia. |
| |
| Keywords: | Leukemia Myelocytic Drug therapy Doxorubicin Mitoxantrone |
| 本文献已被 CNKI 维普 万方数据 等数据库收录！ |
|
